PharmaCyte Biotech (PMCB) Other Gross PP&E Adjustments (2016 - 2025)
PharmaCyte Biotech (PMCB) has disclosed Other Gross PP&E Adjustments for 10 consecutive years, with -$523822.0 as the latest value for Q2 2025.
- On a quarterly basis, Other Gross PP&E Adjustments fell 6.01% to -$523822.0 in Q2 2025 year-over-year; TTM through Oct 2025 was -$523822.0, a 6.01% decrease, with the full-year FY2025 number at -$523822.0, down 6.01% from a year prior.
- Other Gross PP&E Adjustments was -$523822.0 for Q2 2025 at PharmaCyte Biotech, down from -$494130.0 in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of -$369666.0 in Q2 2023 to a low of -$2.5 million in Q2 2021.
- A 5-year average of -$903842.6 and a median of -$523822.0 in 2025 define the central range for Other Gross PP&E Adjustments.
- Peak YoY movement for Other Gross PP&E Adjustments: surged 77.06% in 2022, then plummeted 33.67% in 2024.
- PharmaCyte Biotech's Other Gross PP&E Adjustments stood at -$2.5 million in 2021, then soared by 77.06% to -$584321.0 in 2022, then skyrocketed by 36.74% to -$369666.0 in 2023, then crashed by 33.67% to -$494130.0 in 2024, then dropped by 6.01% to -$523822.0 in 2025.
- Per Business Quant, the three most recent readings for PMCB's Other Gross PP&E Adjustments are -$523822.0 (Q2 2025), -$494130.0 (Q2 2024), and -$369666.0 (Q2 2023).